RecruitingPhase 2NCT06628947

A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa

Studying Retinitis pigmentosa

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Kiora Pharmaceuticals, Inc.
Principal Investigator: Doron Hickey, MBChB
The Centre for Eye Research Australia (CERA)
Intervention: Placebo (Sterile Saline or Balanced Salt Solution)(other)
Enrollment: 36 enrolled
Eligibility: 18 years · All sexes
Timeline: 2025 – 2027

Study locations (5)

Save Sight Institute, Sydney, New South Wales, Australia
Queensland Eye Institute, Woolloongabba, Queensland, Australia
Royal Adelaide Hospital, Adelaide, South Australia, Australia
Cerulea Clinical Trials, East Melbourne, Victoria, Australia
Lions Eye Institute, Nedlands, Western Australia, Australia

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06628947 on ClinicalTrials.gov

Other trials for Retinitis pigmentosa

Additional recruiting or active studies for the same condition.

See all trials for Retinitis pigmentosa →

← Back to all trials